# HDAC9

Source: https://onco.cc/targets/hdac9/  
OnCo record `hdac9` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HDAC9 (Histone deacetylase 9) is a protein that switches other genes on and off. The public catalogues list it as a drug target, a biomarker and a fusion partner, and an approved or late-stage drug is recorded against it. Tied to Breast cancer, Oesophageal cancer, Non-Hodgkin lymphoma and 4 more.

## Summary

Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription.

CIViC holds 3 clinical evidence items and 0 assertions across 2 variants, naming Panobinostat, HDAC Inhibitor REC-2282, Vorinostat and Trichostatin A. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.34, clinical 0.95).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: histone deacetylase 9; Histone deacetylase 9; KIAA0744; HD7; HDAC7B
- Tags: cancer-genes-wave
- Symbol: HDAC9
- Class: transcription
- Biology: Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Represses MEF2-dependent transcription. Isoform 3 lacks active site residues and therefore is catalytically inactive. Represses MEF2-dependent transcription by recruiting HDAC1 and/or HDAC3. Seems to inhibit skeletal myogenesis and to be involved in heart development. Location: Nucleus (UniProt). Locus 7p21.1 (HGNC).
- Where found: Breast cancer: CIViC evidence names this disease; Oesophageal cancer: CIViC evidence names this disease; Non-Hodgkin lymphoma: Open Targets association 0.58 with non-Hodgkin lymphoma (MONDO_0018908); Multiple myeloma: Open Targets association 0.56 with plasma cell myeloma (MONDO_0009693); Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898); Glioma & glioblastoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.95; CIViC holds 3 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:14065: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14065
- UniProt Q9UKV0: https://www.uniprot.org/uniprotkb/Q9UKV0/entry
- NCBI Gene 9734: https://www.ncbi.nlm.nih.gov/gene/9734
- Ensembl ENSG00000048052: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000048052

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/hdac9.json